CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today that the European Medicines Agency has recommended granting a conditional marketing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results